IFNB1 and COVID-19: We also observed that the serum level of IFN-β and IFN-γ were significantly increased in hospitalized COVID-19 patients without comorbidities respect to controls, and the amount of these antiviral mediators were not affected by the presence of multiple comorbidities for patients recruited during the second, but not the first wave (Figures 6E, F).